{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:04:34Z","timestamp":1790647474648,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T00:00:00Z","timestamp":1494201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Anaplastic large cell lymphomas (<jats:styled-content style=\"fixed-case\">ALCL<\/jats:styled-content>s) are rare <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>30+ peripheral T\u2010cell lymphomas (<jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>s) classified according to the expression of the anaplastic lymphoma kinase (<jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content>+) protein or not (<jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content>\u2212). We have analysed the outcome and risk factors for survival in a population\u2010based bi\u2010national cohort of patients with systemic <jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content>+ <jats:styled-content style=\"fixed-case\">ALCL<\/jats:styled-content>. A total of 122 adult (\u226518\u00a0years) patients diagnosed with <jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content>+ <jats:styled-content style=\"fixed-case\">ALCL<\/jats:styled-content> between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0\u00b74% of all lymphomas. The median age of the cohort was 40\u00a0years (range 18\u201385). The 5\u2010year overall survival and progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) was 78% and 64%, respectively. Age was strongly associated with outcome, and only bone marrow (<jats:styled-content style=\"fixed-case\">BM<\/jats:styled-content>) involvement was independently associated with poorer <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> in multivariate analysis (Hazard Ratio [<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>]\u00a0=\u00a08\u00b757, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001). Age stratification of the patients demonstrated an association between treatment with <jats:styled-content style=\"fixed-case\">CHOEP<\/jats:styled-content> (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) and improved overall survival for patients aged 41\u201365\u00a0years, even when adjusted for risk factors (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u00a0=\u00a00\u00b738, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7047). Our results suggest that the addition of etoposide to <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> (cyclophosphamide, doxorubicin, vincristine, prednisolone) in the treatment for <jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content>+ <jats:styled-content style=\"fixed-case\">ALCL<\/jats:styled-content> seems reasonable in this age group.<\/jats:p>","DOI":"10.1111\/bjh.14740","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T02:46:39Z","timestamp":1494297999000},"page":"739-746","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["The addition of etoposide to <scp>CHOP<\/scp> is associated with improved outcome in <scp>ALK<\/scp>+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study"],"prefix":"10.1111","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0728-1549","authenticated-orcid":false,"given":"Henrik","family":"Cederleuf","sequence":"first","affiliation":[{"name":"Oncology and Pathology Department of Clinical Sciences Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bjerreg\u00e5rd Pedersen","sequence":"additional","affiliation":[{"name":"Department of Haematology Aarhus University Hospital Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Oncology and Pathology Department of Clinical Sciences Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Relander","sequence":"additional","affiliation":[{"name":"Oncology and Pathology Department of Clinical Sciences Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"d'Amore","sequence":"additional","affiliation":[{"name":"Department of Haematology Aarhus University Hospital Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9034-5966","authenticated-orcid":false,"given":"Fredrik","family":"Ellin","sequence":"additional","affiliation":[{"name":"Oncology and Pathology Department of Clinical Sciences Lund University Lund Sweden"},{"name":"Department of Internal Medicine Kalmar County Hospital Kalmar Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"e_1_2_8_5_1","unstructured":"De Nully Brown P. J\u00f6rgensen J. Munksgaard L. Amdi Petersen B. Pedersen M. Jensen P.&Klausen T.(2012)Annual report of the Danish Lymphoma Group (2011).http:\/\/www.lymphoma.dk\/wp-content\/uploads\/2016\/11\/Aarsrapport_2011_ver_1_3.pdf"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12360"},{"key":"e_1_2_8_8_1","first-page":"2697","article-title":"ALK+ lymphoma: clinico\u2010pathological findings and outcome","volume":"93","author":"Falini B.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt378"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.11.3913"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567461"},{"key":"e_1_2_8_12_1","unstructured":"Jerkeman M.(2014)Swedish Lymphoma Registry 2000\u20102012 (Regional Cancer Centre South Lund Sweden).http:\/\/www.swedishlymphoma.com\/rapporter"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.5999"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02560.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8122112"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2153"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.5.899"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21438"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.12.3699"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2345"},{"key":"e_1_2_8_24_1","first-page":"2993","article-title":"Prognostic significance of CD56 expression for ALK\u2010positive and ALK\u2010negative anaplastic large\u2010cell lymphoma of T\/null cell phenotype","volume":"96","author":"Suzuki R.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22940"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14740","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T17:08:14Z","timestamp":1696352894000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,8]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/bjh.14740"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14740","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,8]]},"assertion":[{"value":"2016-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}